Orbimed Advisors LLC Next Cure, Inc. Transaction History
Orbimed Advisors LLC
- $4.15 Billion
- Q2 2024
A detailed history of Orbimed Advisors LLC transactions in Next Cure, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 1,141,200 shares of NXTC stock, worth $1.56 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,141,200
Previous 1,141,200
-0.0%
Holding current value
$1.56 Million
Previous $2.54 Million
28.69%
% of portfolio
0.04%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding NXTC
# of Institutions
50Shares Held
16MCall Options Held
1.4KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$3.66 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA2.5MShares$3.43 Million0.37% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.69MShares$2.31 Million0.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$1.35 Million0.0% of portfolio
-
Black Rock Inc. New York, NY761KShares$1.04 Million0.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $38M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...